

27. Silvestri GA, Alberg AJ, Ravenel J. The changing epidemiology of lung cancer with a focus on screening. *BMJ* 2009 (Aug 17); **339**: b3053.
28. Infante M, Cavuto S, Lutman FR, *et al.* A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. *Am J Resp Crit Care Med* 2009; **180**: 445–453.
29. Bepler G. Are we coming full circle for lung cancer screening a second time? *Am J Resp Crit Care Med* 2009; **180**: 384–385.
30. Lovgren M, Levealahti H, Tishelman C, *et al.* Time spans from first symptom to treatment in patients with lung cancer — the influence of symptoms and demographic characteristics. *Acta Oncologica* 2008; **47**: 397–405.
31. NAEDI newsletter. Early Lung Cancer Intervention in Doncaster (ELCiD). London: CRUK, 2009. http://info.cancerresearchuk.org/prod_consump/groups/cr_common/@nre/@hea/documents/generalcontent/013777.pdf (accessed 22 Dec 2009).
32. Speets AM, van der Graaf Y, Hoes AW, *et al.* Chest radiography in general practice: indications, diagnostic yield and consequences for patient management. *Br J Gen Pract* 2006; **56**: 574–578.
33. Stapley S, Sharp D, Hamilton W. Negative chest X-rays in primary care patients with lung cancer. *Br J Gen Pract* 2006; **56**: 570–573.
34. White CS, Flukinger T, Jeudy J, Chen JJ. Use of a computer-aided detection system to detect missed lung cancer at chest radiography. *Radiology* 2009; **252**: 273–281.

COMMENTARY

Cancer diagnosis — the role of urgent referral guidelines

This excellent review brings together evidence from primary care that will undoubtedly help clinicians in their quest for earlier cancer diagnoses for their patients.¹ It is particularly welcome within the current context of the Department of Health's National Awareness and Early Diagnosis Initiative.² Recent policy announcements have focused on easier and quicker access to investigations for GPs for suspected cancer symptoms, and the development and implementation of software for GPs to identify early cancer symptoms within 5 years. Such policies are likely to help save the estimated 5000–10 000 lives per year currently lost in the UK because of probable later diagnosis compared with some European countries.^{3–5} Data from primary care, such as presented in Hamilton's review, will directly inform the development of these policies.

One key policy question is whether urgent referral guidelines are the answer, whatever the quality and quantity of the evidence about the meaning of symptoms. There is a continuing lack of evidence that cancer diagnoses overall are made quicker, and with clinical benefits, through a fast-track system that prioritises some patients over others, based upon their symptoms. Many, quite possibly a majority, of cancers are diagnosed through a more atypical symptomatic presentation, often congruent with symptoms of benign pathology. This is a major challenge for secondary care and for commissioners. Paradoxically, guidelines may prioritise those with least to gain in terms of improved outcomes because they hasten diagnosis of very early tumours that may remain curable and treatable if diagnosed later. They also prioritise those with already established aggressive disease who are beyond curative treatment at the time of diagnosis, although good palliative care for these people may be hastened.⁶ All patients deserve the earliest diagnosis, whatever their symptoms. Guidelines do focus GPs' attention on potential alarm symptoms for cancer.⁷ However, there are also still significant concerns about the implementation and use of the urgent cancer referral guidelines in primary care, which is hugely different to their target driven implementation in secondary care.

In policy terms, there are two main conclusions to be drawn. Firstly, Hamilton is correct in stating that GPs may have too high a threshold for investigation. Gatekeeping has been the cornerstone of the UK NHS for decades. However, for suspected cancer, gatekeeping may be inhibiting early diagnosis and it may be that the balance between referral for opinion or investigation, and minimising costs and the risk of iatrogenic illness needs to be shifted. Watching and waiting is no longer acceptable for certain symptom complexes. Secondly, we need faster routes to diagnostic tests and/or specialist opinion (dependent upon the available diagnostic tests for different cancers) for all patients with a suspicious symptom, above a certain, and as yet undetermined, threshold. A stronger evidence base to enhance our understanding of the predictive value of symptoms will facilitate this.

Richard D Neal,

Senior Lecturer in General Practice, North Wales Clinical School, Department of Primary Care & Public Health, School of Medicine, Cardiff University, Gwenfro Unit 5, Wrexham Technology Park, Wrexham, LL13 7YP. E-mail: nealrd@cf.ac.uk

Provenance

Commissioned; not peer reviewed.

REFERENCES

1. Hamilton W. Cancer diagnosis in primary care. *Br J Gen Pract* 2010; DOI: 10.3399/bjgp10X483175.
2. Richards MA. The National Awareness and Early Diagnosis Initiative in England: assembling the evidence. *Br J Cancer* 2009; **101**: s1–s4.
3. Richards MA. The size of the prize for earlier cancer diagnosis of cancer in England. *Br J Cancer* 2009; **101**: S125–S129.
4. Abdel-Rahman M, Stockton D, Rachet D, *et al.* What if cancer survival in Britain were the same as in Europe: how many deaths are avoidable? *Br J Cancer* 2009; **101**: S115–S124.
5. Moller H, Linklater KM, Robinson D. A visual summary of the EUROCARE-4 results: a UK perspective. *Br J Cancer* 2009; **101**: S110–S114.
6. Neal RD, Allgar VL, Ali N, *et al.* Stage, survival and delays in lung, colorectal, prostate and ovarian cancer: comparison between diagnostic routes. *Br J Gen Pract* 2007; **57**: 212–219.
7. Jones R, Charlton J, Latinovic R, Gulliford MC. Alarm symptoms and identification of non-cancer diagnoses in primary care: cohort study. *BMJ* 2009; **339**: b3094. DOI: 10.1136/bmj.b3094.

DOI: 10.3399/bjgp10X483427